Ingevity Financial Statements
NYSE: NGVTIndustrialsMajor ChemicalsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ingevity revenue and earnings
In fiscal 2025, Ingevity generated $1.17 billion in revenue, down 2.7% from fiscal 2024, its first annual decline since 2024. Ingevity reported a net loss of $167.1 million, compared with a loss of $430.3 million a year earlier. Gross margin was 39.5% (up from 38.7%) and operating margin 35.9%.
Diluted earnings per share came in at -$4.61. Over the last 5 fiscal years, NGVT's revenue has grown at a -0.8% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Ingevity income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17B | 1.20B | 1.22B | 1.67B | 1.39B | 1.22B | 1.29B | 1.13B | 972.40M | 908.30M |
| Revenue growth (YoY) | -2.71% | -1.27% | -27.14% | +19.89% | +14.42% | -5.94% | +14.05% | +16.58% | +7.06% | -5.22% |
| Cost of Revenue | 706.10M | 735.30M | 770.50M | 1.10B | 878.70M | 750.60M | 810.90M | 716.80M | 643.40M | 633.90M |
| Gross Profit | 461.50M | 464.80M | 445.00M | 570.10M | 512.80M | 465.50M | 482.00M | 416.80M | 329.00M | 274.40M |
| Operating Expenses | 42.80M | 38.90M | 21.80M | 117.50M | 90.60M | 67.60M | 85.10M | 96.30M | 86.30M | 110.80M |
| Research & Development | 28.40M | 24.50M | 25.40M | 30.30M | 26.30M | 22.60M | 19.70M | 21.50M | 19.80M | 17.60M |
| Selling, General & Admin | 171.20M | 157.80M | 161.80M | 198.80M | 179.30M | 149.40M | 163.10M | 132.40M | 106.40M | 96.40M |
| Operating Income | 418.70M | 425.90M | 423.20M | 452.60M | 422.20M | 397.90M | 396.90M | 320.50M | 242.70M | 163.60M |
| Interest Expense | 78.30M | 97.80M | 93.30M | 61.80M | 51.70M | 47.10M | 54.60M | 33.20M | 18.10M | 19.30M |
| Other Income (Expense) | -25.00M | -7.90M | 16.20M | 1.70M | -79.90M | 4.10M | 4.30M | -1.00M | -500.00K | 3.20M |
| Pretax Income | -142.10M | -140.50M | 130.00M | 269.60M | 162.80M | 235.10M | 227.90M | 221.80M | 174.80M | 87.00M |
| Income Tax | 8.20M | -19.10M | 24.20M | 58.00M | 44.70M | 53.70M | 44.20M | 40.00M | 29.60M | 42.60M |
| Net Income | -167.10M | -430.30M | -5.40M | 211.60M | 118.10M | 181.40M | 183.70M | 169.10M | 126.50M | 35.20M |
| Net Income growth (YoY) | — | — | -102.55% | +79.17% | -34.90% | -1.25% | +8.63% | +33.68% | +259.38% | -55.83% |
| EPS (Basic) | -4.61 | -11.85 | -0.15 | 5.54 | 2.97 | 4.39 | 4.39 | 4.02 | 3.00 | 0.83 |
| EPS (Diluted) | -4.61 | -11.85 | -0.15 | 5.50 | 2.95 | 4.37 | 4.35 | 3.97 | 2.97 | 0.83 |
| Shares Outstanding (Basic) | 36.22M | 36.32M | 36.50M | 38.18M | 39.82M | 41.33M | 41.80M | 42.04M | 42.13M | 42.11M |
| Shares Outstanding (Diluted) | 36.22M | 36.32M | 36.71M | 38.47M | 40.06M | 41.55M | 42.20M | 42.60M | 42.53M | 42.27M |
| EBITDA | 525.10M | 534.20M | 546.00M | 561.40M | 532.10M | 498.10M | 481.90M | 377.50M | 283.10M | 202.40M |
| Gross Margin | 39.53% | 38.73% | 36.61% | 34.17% | 36.85% | 38.28% | 37.28% | 36.77% | 33.83% | 30.21% |
| Operating Margin | 35.86% | 35.49% | 34.82% | 27.13% | 30.34% | 32.72% | 30.70% | 28.27% | 24.96% | 18.01% |
| Net Margin | -14.31% | -35.86% | -44.00% | 12.68% | 8.49% | 14.92% | 14.21% | 14.92% | 13.01% | 3.88% |
This table shows 10 annual periods of Ingevity's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NGVT's reporting calendar. What is a income statement?